Zyrtec OTC, New Segments Picked Up From Pfizer Will Be Key Drivers – J&J
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson is optimistic about potential earnings from an anticipated OTC launch of Zyrtec (cetirizine HCl) allergy medication late in 2007, company Chairman and CEO William C. Weldon said during a Jan. 23 conference call on the firm's 2006 fourth-quarter and full-year earnings